3HP FAQs for Providers | Tools for Health Care Providers | Professional Resources & Tools | TB | CDC

3HP FAQs for Providers | Tools for Health Care Providers | Professional Resources & Tools | TB | CDC

3HP FAQs for Providers

Expand All  Collapse All 

What is latent tuberculosis infection (LTBI)?

Why is treatment of latent TB infection important?

How is latent TB infection diagnosed?

Who should be given high priority for latent TB infection treatment?

What treatment regimens are available to treat latent TB infection?

What is 3HP?

Why is CDC updating recommendations for 3HP?

Who is recommended for treatment of latent TB infection with 3HP?

Who is not recommended for treatment of latent TB infection with 3HP?

Who is recommended for self-administered therapy (SAT) with 3HP?

Can parents administer 3HP to children under 18 years old?

How should patients be evaluated prior to beginning 3HP?

How should providers educate patients about possible adverse events?

How should providers educate patients about taking the medication on schedule?

When should providers advise patients stop 3HP?

Who should providers contact if they have questions?

CDC Guidance

• Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
• Information for Clinicians: The 12-Dose Regimen for Latent Tuberculosis (TB) Infection[PDF – 134 KB]
• Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
• Latent Tuberculosis Infection: A Guide for Primary Health Care Providers
• Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection (slide set)
• Latent Tuberculosis Infection Resources Hub
• Patient Education Materials
  • 12-Dose Regimen for Latent TB Infection
  • Symptom Checklist
  • Medication Intake Log